Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter, open label, non-inferiority, randomized controlled clinical study. The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin + cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab (PLD + C + HP followed by THP) regimen compared with a docetaxel + carboplatin plus trastuzumab and pertuzumab (TCbHP) regimen in the neoadjuvant treatment of HER-2-positive breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18–70 lat
- •Potwierdzony histologicznie rak piersi bez wcześniejszego leczenia
- •Pozytywny HER-2 (potwierdzone badaniami)
- •Guz większy niż 2 cm
- •Potwierdzenie przerzutów do węzłów chłonnych w ostatnich 28 dniach
- •Co najmniej jedno zmierzalne ognisko nowotworu
- •Dobra wydolność fizyczna (ECOG 0 lub 1)
- •Prawidłowa funkcja serca, wątroby i nerek
✗ Disqualifies
- •Rak piersi z przerzutami na odległe organy
- •Guzy w różnych częściach piersi lub rak obu piersi
- •Wcześniejsze leczenie przeciwnowotworowe (z wyjątkami dla LCIS/DCIS sprzed >5 lat)
- •Poważne problemy z sercem lub nieskontrolowane zaburzenia rytmu serca
- •Niekontrolowane nadciśnienie tętnicze
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- February 2, 2024
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Sunyat-sen Memorial Hospital
Guandong, China
Trial contact
Qiang Liu, PhD
Qiang Liu, PhD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.